Keywords
Breast Cancer
ovarian cancer
How to Cite
Abstract
Breast cancer is the most common malignancy in women worldwide with more than 2.2 million newly diagnosed cases and more than 650,000 deaths annually. Triple-negative breast cancer accounts for 15-20% of all breast cancer cases and is characterized by aggressive behavior. Androgen receptor is considered as a possible new biomarker and potential therapeutic target in the treatment of breast cancer. Androgen receptor inhibitors may be considered a therapeutic option for specific subtypes of breast cancer. It plays a particularly important role in the carcinogenesis of triple-negative breast cancer. However, the issue of its active implementation in management is still controversial. Ovarian cancer is a gynecological malignancy diagnosed at an advanced stage in most cases and has different cellular origin, histological characteristics and therapeutic response. Epidemiological and experimental evidence suggests the involvement of androgens in the development of ovarian tumors. However, the influence of the androgen receptor in patients with epithelial ovarian tumors is still a subject of active study. Some studies have shown that androgen receptor overexpression is associated with good survival rates. There are also studies that show no significant association between steroid receptor expression and overall survival.
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209–49.
დაავადებათა კონტროლის და საზოგადოებრივი ჯანმრთელობის ეროვნული ცენტრი 2.
Kolyvas EA, Caldas C, Kelly K, Ahmad SS. Androgen receptor function and targeted therapeutics across breast cancer subtypes. Breast Cancer Research. 2022 Nov 14;24(1):79. 4. Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 Jan;21(1):44–59.
Kepuladze S, Kokhreidze I, Burkadze G. COMPARING CHANGES IN EPITHELIAL-MESENCHYMAL TRANSFORMATION MARKERS IN DIFFERENT TUMOR SITES OF BREAST CANCER WITH HER2-POSITIVE MOLECULAR SUBTYPE. GEORGIAN SCIENTISTS. 2023 May 16;
Handelsman DJ, Hirschberg AL, Bermon S. Circulating Testosterone as the Hormonal Basis of Sex Differences in Athletic Performance. Endocr Rev. 2018 Oct 1;39(5):803–29.
Gerratana L, Basile D, Buono G, De Placido S, Giuliano M, Minichillo S, et al. Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. Cancer Treat Rev. 2018 Jul;68:102–10.
Kepuladze S, Kokhreidze I, Burkadze G. Comparative analysis of phenotypic features in the primary tumor, tumour buds and metastatic lymph nodes within Luminal A and Luminal B molecular subtypes of invasive ductal carcinoma of the breast. GEORGIAN SCIENTISTS. 2022 Apr 11;
Gucalp A, Traina TA. Targeting the androgen receptor in triple-negative breast cancer. Curr Probl Cancer [Internet]. 2016 Mar 1 [cited 2023 Jul 30];40(2–4):141–50. Available from: https://pubmed.ncbi.nlm.nih.gov/27816190/
Barton VN, Christenson JL, Gordon MA, Greene LI, Rogers TJ, Butterfield K, et al. Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer. Cancer Res. 2017 Jul 1;77(13):3455–66.
Varas-Godoy M, Rice G, Illanes SE. The Crosstalk between Ovarian Cancer Stem Cell Niche and the Tumor Microenvironment. Stem Cells Int [Internet]. 2017 [cited 2023 Jul 30];2017. Available from: /pmc/articles/PMC5551518/
Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin [Internet]. 2018 Jul 1 [cited 2023 Jul 30];68(4):284–96. Available from: https://onlinelibrary.wiley.com/doi/full/10.3322/caac.21456
Peres LC, Cushing-Haugen KL, Anglesio M, Wicklund K, Bentley R, Berchuck A, et al. Histotype classification of ovarian carcinoma: A comparison of approaches. Gynecol Oncol [Internet]. 2018 Oct 1 [cited 2023 Jul 30];151(1):53. Available from: /pmc/articles/PMC6292681/
Duska LR, Kohn EC. The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications. Ann Oncol [Internet]. 2017 Nov 1 [cited 2023 Jul 30];28(suppl_8):viii8–12. Available from: https://pubmed.ncbi.nlm.nih.gov/29232468/
Meinhold-Heerlein I, Fotopoulou C, Harter P, Kurzeder C, Mustea A, Wimberger P, et al. The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications. Arch Gynecol Obstet [Internet]. 2016 Apr 1 [cited 2023 Jul 30];293(4):695–700. Available from: https://pubmed.ncbi.nlm.nih.gov/26894303/
Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature [Internet]. 2015 May 28 [cited 2023 Jul 30];521(7553):489–94. Available from: https://pubmed.ncbi.nlm.nih.gov/26017449/
Wilbur MA, Shih IM, Segars JH, Fader AN. Cancer Implications for Patients with Endometriosis. Semin Reprod Med [Internet]. 2017 Jan 1 [cited 2023 Jul 30];35(1):110–6. Available from: https://pubmed.ncbi.nlm.nih.gov/28049216/
Hollis RL, Gourley C. Genetic and molecular changes in ovarian cancer. Cancer Biol Med [Internet]. 2016 Jun 1 [cited 2023 Jul 30];13(2):236–47. Available from: https://pubmed.ncbi.nlm.nih.gov/27458531/
Mizushima T, Miyamoto H. The Role of Androgen Receptor Signaling in Ovarian Cancer. Cells. 2019 Feb 19;8(2):176.
Yarmolinsky J, Relton CL, Lophatananon A, Muir K, Menon U, Gentry-Maharaj A, et al. Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: A Mendelian randomization analysis. PLoS Med [Internet]. 2019 [cited 2023 Jul 30];16(8). Available from: https://pubmed.ncbi.nlm.nih.gov/31390370/
La Vecchia C. Ovarian cancer: epidemiology and risk factors. Eur J Cancer Prev [Internet]. 2017 Jan 1 [cited 2023 Jul 30];26(1):55–62. Available from: https://pubmed.ncbi.nlm.nih.gov/26731563/
Liao Y, Tu C, Song X, Cai L. Case report: Analysis of BRCA1 and BRCA2 gene mutations in a hereditary ovarian cancer family. J Assist Reprod Genet [Internet]. 2020 Jun 1 [cited 2023 Jul 30];37(6):1489. Available from: /pmc/articles/PMC7311593/
Li H, Liu Y, Wang Y, Zhao X, Qi X. Hormone therapy for ovarian cancer: Emphasis on mechanisms and applications (Review). Oncol Rep. 2021 Aug 26;46(4):223.
Ose J, Poole EM, Schock H, Lehtinen M, Arslan AA, Zeleniuch-Jacquotte A, et al. Androgens Are Differentially Associated with Ovarian Cancer Subtypes in the Ovarian Cancer Cohort Consortium. Cancer Res [Internet]. 2017 Jul 15 [cited 2023 Jul 30];77(14):3951–60. Available from: https://pubmed.ncbi.nlm.nih.gov/28381542/
Trabert B, Michels KA, Anderson GL, Brinton LA, Falk RT, Geczik AM, et al. Circulating androgens and postmenopausal ovarian cancer risk in the Women’s Health Initiative Observational Study. Int J Cancer [Internet]. 2019 Oct 10 [cited 2023 Jul 30];145(8):2051. Available from: /pmc/articles/PMC6660427/
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2023 GEORGIAN SCIENTISTS